Abstract
BackgroundAutism spectrum disorder (ASD) is a neurodevelopmental disorder with a worldwide prevalence of 1–2%. In low-resource environments, in particular, early identification and diagnosis is a significant challenge. Therefore, there is a great demand for ‘language-free, culturally fair’ low-cost screening tools for ASD that do not require highly trained professionals. Electroencephalography (EEG) has seen growing interest as an investigational tool for biomarker development in ASD and neurodevelopmental disorders. One of the key challenges is the identification of appropriate multivariate, next-generation analytical methodologies that can characterise the complex, nonlinear dynamics of neural networks in the brain, mindful of technical and demographic confounders that may influence biomarker findings. The aim of this study was to evaluate the robustness of recurrence quantification analysis (RQA) as a potential biomarker for ASD using a systematic methodological exploration of a range of potential technical and demographic confounders.MethodsRQA feature extraction was performed on continuous 5-second segments of resting state EEG (rsEEG) data and linear and nonlinear classifiers were tested. Data analysis progressed from a full sample of 16 ASD and 46 typically developing (TD) individuals (age 0–18 years, 4802 EEG segments), to a subsample of 16 ASD and 19 TD children (age 0–6 years, 1874 segments), to an age-matched sample of 7 ASD and 7 TD children (age 2–6 years, 666 segments) to prevent sample bias and to avoid misinterpretation of the classification results attributable to technical and demographic confounders. A clinical scenario of diagnosing an unseen subject was simulated using a leave-one-subject-out classification approach.ResultsIn the age-matched sample, leave-one-subject-out classification with a nonlinear support vector machine classifier showed 92.9% accuracy, 100% sensitivity and 85.7% specificity in differentiating ASD from TD. Age, sex, intellectual ability and the number of training and test segments per group were identified as possible demographic and technical confounders. Consistent repeatability, i.e. the correct identification of all segments per subject, was found to be a challenge.ConclusionsRQA of rsEEG was an accurate classifier of ASD in an age-matched sample, suggesting the potential of this approach for global screening in ASD. However, this study also showed experimentally how a range of technical challenges and demographic confounders can skew results, and highlights the importance of probing for these in future studies. We recommend validation of this methodology in a large and well-matched sample of infants and children, preferably in a low- and middle-income setting.
Highlights
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with a worldwide prevalence of 1–2%
recurrence quantification analysis (RQA) of resting state EEG (rsEEG) was an accurate classifier of ASD in an age-matched sample, suggesting the potential of this approach for global screening in ASD
Full sample: cross-validation approach The optimal parameter set identified was comprised of an embedding lag of 25, embedding dimension of 10, percentage variance to retain (PVR) of 22.12 (equivalent to six principal components (PCs)) and a neighbourhood size of 3.0
Summary
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with a worldwide prevalence of 1–2%. A biomarker that can screen and identify those at risk for a condition for which early intervention is available could be valuable In such a scenario, the biomarker should be able to classify an individual as ‘at risk’ in comparison to population-based peers. Autism spectrum disorder (ASD) has a global prevalence estimate of 1–2% in children [4,5,6,7,8]; 90% of people with ASD live in low- and middle-income countries [9], where there is a significant demand for low-cost screening tools that do not require highly trained professionals [3, 9,10,11]. Identification is an essential first step to prevent unnecessary delays in access to early intervention strategies, parent education and planning for longer-term support [12,13,14,15]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.